Pyxis Oncology (PYXS) Accounts Payables (2020 - 2025)

Pyxis Oncology (PYXS) has 6 years of Accounts Payables data on file, last reported at $10.9 million in Q4 2025.

• Accounts Payables for Q4 2025 came in at $10.9 million, up 124.02% year-over-year; the trailing twelve-month figure through Dec 2025 was $10.9 million (up 124.02% YoY), and the FY2025 annual result was $10.9 million, up 124.02% from the prior year.
• Accounts Payables rose to $10.9 million in Q4 2025 per PYXS's latest filing, from $9.8 million in the prior quarter.
• Over five years, Accounts Payables peaked at $12.0 million in Q4 2021 and troughed at $1.3 million in Q2 2023.
• A 5-year average of $5.5 million and a median of $4.9 million in 2024 frame the typical range for Accounts Payables.
• The sharpest annual moves came in 2021 and 2023: Accounts Payables surged 1009.66% in 2021, then slumped 83.31% in 2023.
• A 5-year view of Accounts Payables shows it stood at $12.0 million in 2021, then sank by 40.62% to $7.1 million in 2022, then slumped by 45.1% to $3.9 million in 2023, then gained by 24.72% to $4.9 million in 2024, then surged by 124.02% to $10.9 million in 2025.
• Business Quant data shows PYXS's Accounts Payables at $10.9 million in Q4 2025, $9.8 million in Q3 2025, and $9.4 million in Q2 2025.